Cargando…

Clinical Benefit from Tyrosine Kinase Inhibitors in Metastatic Merkel Cell Carcinoma: A Case Series of 5 Patients

Case series Patients: Male, 58 • Male, 65 • Male, 75 • Male, 61 • Male, 69 Final Diagnosis: Merkel cell carcinoma Symptoms: Metastatic disease Medication: Pazopanib • Cabozantinib Clinical Procedure: Systemic therapy Specialty: Oncology OBJECTIVE: Rare disease BACKGROUND: Merkel cell carcinoma (MCC)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tarabadkar, Erica S., Thomas, Hannah, Blom, Astrid, Parvathaneni, Upendra, Olencki, Thomas, Nghiem, Paul, Bhatia, Shailender
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5952731/ https://www.ncbi.nlm.nih.gov/pubmed/29706615 http://dx.doi.org/10.12659/AJCR.908649

Ejemplares similares

Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma
por: Iyer, Jayasri G., et al.
Publicado: (2016)

Single-fraction radiation therapy in patients with metastatic Merkel cell carcinoma
por: Iyer, Jayasri G, et al.
Publicado: (2015)

How we treat Merkel cell carcinoma: within and beyond current guidelines
por: Park, Song Y, et al.
Publicado: (2021)

Postoperative radiation therapy is associated with a reduced risk of local recurrence among low risk Merkel cell carcinomas of the head and neck
por: Takagishi, Seesha R., et al.
Publicado: (2016)

Management and Prognosis of Cardiac Metastatic Merkel Cell Carcinoma: A Case–Control Study and Literature Review
por: Akaike, Tomoko, et al.
Publicado: (2022)

Complete resolution of PD-1 refractory, locoregionally advanced Merkel cell carcinoma with talimogene laherparepvec
por: Singh, Neha, et al.
Publicado: (2023)

Postoperative, Single-Fraction Radiation Therapy in Merkel Cell Carcinoma of the Head and Neck
por: Cook, Maclean M., et al.
Publicado: (2020)

Systemic immune suppression as a stage-independent predictor of diminished Merkel cell carcinoma-specific survival
por: Paulson, Kelly G., et al.
Publicado: (2012)

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
por: Kaufman, Howard L., et al.
Publicado: (2018)

Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy
por: Miller, Natalie J., et al.
Publicado: (2018)

Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
por: D'Angelo, Sandra P, et al.
Publicado: (2020)

Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study
por: Bhatia, Shailender, et al.
Publicado: (2022)

Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma
por: D’Angelo, Sandra P., et al.
Publicado: (2019)

Immunotherapy for Merkel cell carcinoma: a turning point in patient care
por: Chan, Isaac S., et al.
Publicado: (2018)

Patterns of distant metastases in 215 Merkel cell carcinoma patients: Implications for prognosis and surveillance
por: Lewis, Christopher W., et al.
Publicado: (2019)

Case Report: Favorable Response to the Tyrosine Kinase Inhibitor Apatinib in Recurrent Merkel Cell Carcinoma
por: Feng, Yiyi, et al.
Publicado: (2021)

Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series
por: LoPiccolo, Jaclyn, et al.
Publicado: (2019)

Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up
por: D'Angelo, S.P., et al.
Publicado: (2021)

Vascular E-selectin expression correlates with CD8 lymphocyte infiltration and improved outcome in Merkel cell carcinoma
por: Afanasiev, Olga K., et al.
Publicado: (2013)

Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma
por: Tachiki, Lisa May Ling, et al.
Publicado: (2023)

Differential Toxicities of Tyrosine Kinase Inhibitors in the Management of Metastatic Lung Cancer
por: Udupa, Karthik S, et al.
Publicado: (2017)

Complete Spontaneous Regression of Merkel Cell Carcinoma Metastatic to the Liver: Did Lifestyle Modifications and Dietary Supplements Play a Role?
por: Vandeven, Natalie, et al.
Publicado: (2012)

Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
por: Nghiem, Paul, et al.
Publicado: (2021)

An Extremely Rare Case of Metastatic Merkel Carcinoma of the Liver
por: Thomas, Mathew, et al.
Publicado: (2021)

Immune checkpoint inhibitor therapy in HIV-associated Merkel cell carcinoma: A case series of 3 patients
por: Park, Song Y., et al.
Publicado: (2020)

The two facets of receptor tyrosine kinase in cardiovascular calcification—can tyrosine kinase inhibitors benefit cardiovascular system?
por: Masbuchin, Ainun Nizar, et al.
Publicado: (2022)

Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma
por: Nghiem, Paul, et al.
Publicado: (2017)

Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma
por: Poddubskaya, Elena V., et al.
Publicado: (2018)

Predictors of immunotherapy benefit in Merkel cell carcinoma
por: Kacew, Alec J., et al.
Publicado: (2020)

Association of Merkel Cell Polyomavirus–Specific Antibodies With Merkel Cell Carcinoma
por: Carter, Joseph J., et al.
Publicado: (2009)

Identification of a Novel Series of Potent TrkA Receptor Tyrosine Kinase Inhibitors
por: Raeppel, Stéphane L., et al.
Publicado: (2012)

Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy
por: Goh, Gerald, et al.
Publicado: (2015)

First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study
por: D'Angelo, Sandra P, et al.
Publicado: (2021)

Metastatic Merkel cell carcinoma response to nivolumab
por: Walocko, Frances M., et al.
Publicado: (2016)

Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer
por: Cabanillas, Maria E., et al.
Publicado: (2011)

Does a new polyomavirus contribute to Merkel cell carcinoma?
por: Garneski, Kelly M, et al.
Publicado: (2008)

In Regard to Barker
por: Goff, Peter H., et al.
Publicado: (2021)

Co-administration of tyrosine kinase inhibitors with rottlerin in metastatic prostate cancer cells
por: Cieslikowski, Wojciech A., et al.
Publicado: (2021)

Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
por: Catalano, Martina, et al.
Publicado: (2022)

Epidemiology of Merkel Cell Polyomavirus Infection and Merkel Cell Carcinoma
por: Silling, Steffi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5kmits09sq61ldled4jsu60d6r